Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer.
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
Get TOP in Your Inbox
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!